MA41072A1 - Nouvelles protéines spécifiques de la pyoverdine et de la pyochéline - Google Patents

Nouvelles protéines spécifiques de la pyoverdine et de la pyochéline

Info

Publication number
MA41072A1
MA41072A1 MA41072A MA41072A MA41072A1 MA 41072 A1 MA41072 A1 MA 41072A1 MA 41072 A MA41072 A MA 41072A MA 41072 A MA41072 A MA 41072A MA 41072 A1 MA41072 A1 MA 41072A1
Authority
MA
Morocco
Prior art keywords
pyoverine
pyochelin
new
specific proteins
relates
Prior art date
Application number
MA41072A
Other languages
English (en)
Inventor
Carsten Corvey
Heike Stump
Jochen Kruip
Bernhard Calandra
Astrid Rey
Nathalie Karst
Michael Mourez
Laurent Fraisse
Christine Rothe
Andrea Allersdorfer
Alexander Wiedenmann
Marlon Hinner
Bradley Lunde
Kristian Jensen
Martin Hülsmeyer
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA41072A1 publication Critical patent/MA41072A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des mutéines de hngal qui se lient à un membre de la famille pyoverdine ou pyochéline et qui peuvent être utilisées dans diverses applications, y compris des applications pharmaceutiques, par exemple, pour inhiber ou réduire la croissance de p. Aeruginosa. La présente invention concerne également des procédés de fabrication d'une ou plusieurs mutéines de liaison à la pyoverdine ou à la pyochéline décrites ici ainsi que de compositions comprenant une ou plusieurs de ces mutéi
MA41072A 2015-02-18 2016-02-16 Nouvelles protéines spécifiques de la pyoverdine et de la pyochéline MA41072A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15305242 2015-02-18
PCT/EP2016/053226 WO2016131804A1 (fr) 2015-02-18 2016-02-16 Nouvelles protéines spécifiques de la pyoverdine et de la pyochéline

Publications (1)

Publication Number Publication Date
MA41072A1 true MA41072A1 (fr) 2018-10-31

Family

ID=52595246

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41072A MA41072A1 (fr) 2015-02-18 2016-02-16 Nouvelles protéines spécifiques de la pyoverdine et de la pyochéline

Country Status (28)

Country Link
US (8) US9884898B2 (fr)
EP (1) EP3259282A1 (fr)
JP (1) JP6843754B2 (fr)
KR (1) KR20170116158A (fr)
CN (1) CN107660211A (fr)
AR (1) AR103714A1 (fr)
AU (1) AU2016221816B2 (fr)
BR (1) BR112017017530A2 (fr)
CA (1) CA2976687A1 (fr)
CL (1) CL2017002082A1 (fr)
CO (1) CO2017009433A2 (fr)
CR (1) CR20170425A (fr)
DO (1) DOP2017000191A (fr)
EA (1) EA035824B1 (fr)
EC (1) ECSP17061751A (fr)
GT (1) GT201700184A (fr)
HK (1) HK1245293A1 (fr)
IL (1) IL254013A0 (fr)
MA (1) MA41072A1 (fr)
MX (1) MX375049B (fr)
PE (1) PE20171652A1 (fr)
PH (1) PH12017501473A1 (fr)
SG (1) SG11201706621SA (fr)
TN (1) TN2017000348A1 (fr)
TW (1) TW201636364A (fr)
UY (1) UY36561A (fr)
WO (1) WO2016131804A1 (fr)
ZA (1) ZA201705257B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012013662B1 (pt) 2009-12-07 2022-08-02 Pieris Pharmaceuticals Gmbh Muteínas de lipocalina associada à gelatinase de neutrófilo humano (lcn2, hngal), seu uso e seus métodos de geração e produção, molécula de ácido nucleico, célula hospedeira, composição farmacêutica e kit de diagnóstico ou analítico
EP3145945B1 (fr) 2014-05-22 2020-07-15 Pieris Pharmaceuticals GmbH Nouveaux polypeptides de liaison spécifique et utilisations associées
SG11201705278QA (en) 2015-01-28 2017-07-28 Pieris Pharmaceuticals Gmbh Novel proteins specific for angiogenesis
EP3259282A1 (fr) * 2015-02-18 2017-12-27 Sanofi Nouvelles protéines spécifiques de la pyoverdine et de la pyochéline
PH12017501583B1 (en) 2015-05-04 2023-01-20 Pieris Pharmaceuticals Gmbh Novel proteins specific for cd137
RU2727165C2 (ru) 2015-05-04 2020-07-21 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Слитый полипептид с противораковой активностью
EP3298029A1 (fr) 2015-05-18 2018-03-28 Pieris Pharmaceuticals GmbH Mutéines de la lipocaline 2 humaine avec affinité pour glypican-3 (gpc3)
DK3298030T5 (en) 2015-05-18 2024-10-07 Pieris Pharmaceuticals Gmbh Anti-cancerfusionspolypeptid
EP3115371A1 (fr) * 2015-07-07 2017-01-11 Sanofi Molécules de fusion
US10703810B2 (en) 2015-11-30 2020-07-07 Pieris Australia Pty Ltd. Fusion polypeptides which bind vascular endothelial growth factor a (VEGF-A) and angiopoietin-2 (Ang-2)
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
WO2018087108A1 (fr) * 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Protéines spécifiques de cd137
CN113226360A (zh) * 2018-07-19 2021-08-06 科罗拉多大学评议会 用于肠杆菌素治疗铁缺乏和相关贫血的新用途的方法、系统和组合物
CN113939307A (zh) 2019-03-29 2022-01-14 皮里斯制药有限公司 脂质运载蛋白突变蛋白的吸入施用
CN116077621B (zh) * 2021-11-05 2026-03-24 华南农业大学 P19蛋白在调控绿脓杆菌毒力中的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (fr) 1998-03-31 1999-09-30 Hemosol Inc. Complexes d'amidon hydroxyethyles d'hemoglobine
JP3839667B2 (ja) 1998-06-08 2006-11-01 エフ．ホフマン−ラ ロシュ アーゲー 慢性Ｃ型肝炎の処置のためのＰｅｇ−ＩＮＦ−アルファ及びリバビリンの使用
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
JP4469456B2 (ja) * 2000-04-19 2010-05-26 第一三共株式会社 緑膿菌鉄獲得系阻害物質のスクリーニング法
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
US7056702B2 (en) * 2002-12-16 2006-06-06 Kimberly Clark Co Detecting lipocalin
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
AU2006294644A1 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
US8420051B2 (en) 2008-06-24 2013-04-16 Technische Universitaet Meunchen Muteins of hNGAL and related proteins with affinity for a given target
JP2013529907A (ja) * 2010-05-24 2013-07-25 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク Ｎｇａｌタンパク質変異体及びその使用
EP2920202B1 (fr) 2012-11-19 2018-08-29 Pieris Pharmaceuticals GmbH Nouveaux polypeptides se liant specifiquement, et leur utilisation
CN103074303A (zh) * 2012-12-27 2013-05-01 中国人民解放军第三军医大学 产生抗人ngal特异性单克隆抗体的杂交瘤细胞株及其产生的单克隆抗体与应用
EP3259282A1 (fr) * 2015-02-18 2017-12-27 Sanofi Nouvelles protéines spécifiques de la pyoverdine et de la pyochéline
EP3115371A1 (fr) 2015-07-07 2017-01-11 Sanofi Molécules de fusion

Also Published As

Publication number Publication date
US20180037619A1 (en) 2018-02-08
US20180086799A1 (en) 2018-03-29
AU2016221816A1 (en) 2017-10-12
UY36561A (es) 2016-09-30
US20180037618A1 (en) 2018-02-08
GT201700184A (es) 2018-10-24
JP6843754B2 (ja) 2021-03-17
US10118952B2 (en) 2018-11-06
CL2017002082A1 (es) 2018-04-27
CO2017009433A2 (es) 2017-11-30
EA201791841A1 (ru) 2018-01-31
PH12017501473A1 (en) 2018-01-29
US9884898B2 (en) 2018-02-06
US20180371037A1 (en) 2018-12-27
AR103714A1 (es) 2017-05-31
TN2017000348A1 (en) 2019-01-16
DOP2017000191A (es) 2017-09-29
TW201636364A (zh) 2016-10-16
JP2018506979A (ja) 2018-03-15
US10072056B2 (en) 2018-09-11
US10065998B2 (en) 2018-09-04
KR20170116158A (ko) 2017-10-18
CR20170425A (es) 2017-11-22
MX375049B (es) 2025-03-06
ZA201705257B (en) 2019-06-26
MX2017010628A (es) 2017-12-07
PE20171652A1 (es) 2017-11-13
US20170267734A1 (en) 2017-09-21
EA035824B1 (ru) 2020-08-17
SG11201706621SA (en) 2017-09-28
US20180346532A1 (en) 2018-12-06
CA2976687A1 (fr) 2016-08-25
CN107660211A (zh) 2018-02-02
WO2016131804A1 (fr) 2016-08-25
ECSP17061751A (es) 2017-10-31
US20180371038A1 (en) 2018-12-27
US20180030101A1 (en) 2018-02-01
EP3259282A1 (fr) 2017-12-27
IL254013A0 (en) 2017-10-31
HK1245293A1 (zh) 2018-08-24
AU2016221816B2 (en) 2020-07-02
BR112017017530A2 (pt) 2018-04-17
US10329334B2 (en) 2019-06-25

Similar Documents

Publication Publication Date Title
MX2025002516A (es) Molecula que tiene utilidad pesticida, y composiciones y procedimientos relacionados con la misma
MX2023000289A (es) Moleculas que tienen utilidad plaguicida, e intermediarios, composiciones, y procesos, relacionados a las mismas.
MA39727A (fr) Compositions antimicrobiennes pour végétaux
MA46708B1 (fr) Anticorps anti-pd1 et leurs utilisations
FR3044900B1 (fr) Agents nettoyants tensioactifs comportant au moins trois agents conservateurs differents
ZA201706381B (en) Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto
MA38393A3 (fr) Composés hétéroaryle et utilisations associées
MA52545B1 (fr) Anticorps pour radionucléides chélatés
MX2018008846A (es) Moléculas que tienen utilidad plaguicida, e intermediarios, composiciones y procesos relacionados con ellas.
EA200970916A1 (ru) Соединения 5,6-дигидро-1н-пиридин-2-она
PH12017501473A1 (en) Novel proteins specific for pyoverdine and pyochelin
MX2017002054A (es) Moleculas que tienen ciertas utilidades pesticidas y productos intermediarios, composiciones y procesos relacionados con las mismas.
MX394795B (es) Moleculas que tienen cierta utilidad pesticida, intermedios, composiciones y procesos relacionados con las mismas.
MX2017000313A (es) Moleculas que tienen cierta utilidad plaguicida e intermediarios, composiciones y procedimientos relacionados con las mismas.
MX2018008845A (es) Moléculas que tienen utilidad plaguicida, e intermediarios, composiciones y procesos, relacionados con ellas.
MX2018002332A (es) Moleculas que tienen utilidad plaguicida, e intermediarios, composiciones y procesos, relacionados con ellas.
WO2017062500A3 (fr) Activateurs de flux autophagique et de phospholipase d et clairance d'agrégats de protéines comprenant tau et traitement de protéinopathies
MA38369B1 (fr) Peptides et compositions pour le traitement d'une lesion de l'articulation
MX2018002331A (es) Moleculas que tienen utilidad plaguicida, e intermediarios, composiciones y procesos, relacionados con ellas.
FR3063645B1 (fr) Acefapc pour le traitement des maladies acetylcholine dependantes
MA34135B1 (fr) Protéines de liaison à un antigène spécifiques pour un composant p de substance amyloïde sérique
MA42006A1 (fr) Molécules hybrides
MA38699A1 (fr) Formulation orale pour le traitement de maladies cardiovasculaires
MX2018002336A (es) Moleculas que tienen utilidad plaguicida, e intermediarios, composiciones y procesos, relacionados con ellas.
MA45609B1 (fr) Compositions d'acide cromoglicique pour le traitement de la dermatite